229975-97-7

• 常用中文名：阿扎那韦硫酸盐
• 常用英文名：Atazanavir sulfate
• CAS号：229975-97-7
• 分子式：C₃₈H₅₄N₆O₁₁S
• 分子量：802.934
• 相关类别： 原料药 抗生素类药物 其它抗生素类药
• 发布时间：2018-08-24 11:44:48
• 更新时间：2026-07-05 20:20:23
• Atazanavir硫酸盐是HIV-1蛋白酶高活性抑制剂。

名称

• 中文名: 阿扎那韦硫酸盐
• 英文名: atazanavir sulfate
• 中文别名: 硫酸阿扎那韦 硫酸酯; 阿扎那韦(硫酸盐)(ATAZANAVIR); 阿扎那韦硫酸盐, HIV PROTEASE抑制剂; 硫酸阿扎那韦; 阿扎那韦杂质32; 阿扎那韦硫酸盐(标准品); 西洛司特; 阿扎那韦 其他西药原料; ((5S,10S,11S,14S)-11-苄基-5-(叔丁基)-10-羟基-15,15-二甲基-3,6,13-三氧代-8-(4-(吡啶-2-基)苄基)-2-氧杂-4,7,8,12-四氮杂十六烷-14-基)氨基甲酸甲酯 硫酸盐; 硫酸阿扎那韦,10 MM DMSO 溶液; 阿扎那韦硫酸盐 REYATAZ
• 英文别名: Atazanavir sulfate (BMS-232632-05); Zrivada; Zrivada {Sulfate}; methyl [(1S,4S,5S,10S)-4-benzyl-1,10-di-tert-butyl-5-hydroxy-2,9,12-trioxo-7-(4-pyridin-2-ylbenzyl)-13-oxa-3,7,8,11-tetraazatetradec-1-yl]carbamate sulfate (salt); BMS-232632-05 {Sulfate}; Methyl {(5S,10S,11S,14S)-11-benzyl-10-hydroxy-15,15-dimethyl-5-(2-methyl-2-propanyl)-3,6,13-trioxo-8-[4-(2-pyridinyl)benzyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl}carbamate sulfate (1:1) (non-preferred name); Butanoic acid, 2-[(methoxycarbonyl)amino]-3,3-dimethyl-, 2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethyl-1-oxobutyl]amino]-4-phenylbutyl]-2-[[4-(2-pyridinyl)phenyl]methyl]hydrazide, (2S)-, sulfate (1:1) (salt); Atazanavir (BMS-232632) sulfate; ATAZANAVIR SULFATE (NON-STERILE DRUG SUBSTANCE); Dimethyl (3S,8S,9S,12S)-9-benzyl-3,12,di-tert-butyl-8-hydroxy-4,11-dioxo-6-(p-2-pyridylbenzyl)-2,5,6,10,13-pentaazatetradecanedioate sulfate; N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycbonylamino)-3,3-dimethyl-1-oxobutyl]amino]-4-phenylbutyl]-2-[(4-phenylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]cbamic acid methyl; Atazanavir Bisulfate Salt; BMS 232632 sulfate; Atazanavir sulfateQ: What is Atazanavir sulfate Q: What is the CAS Number of Atazanavir sulfate Q: What is the storage condition of Atazanavir sulfate Q: What e the applications of Atazanavir sulfate; Atazanavir sulfate HIV protease inhibitors; Atazanavir Sulfate (Latazanavir, Zrivada, Reyataz, BMS232632); [(1S,4S,5S,10S)-4-benzyl-1,10-bis(1,1-diméthyléthyl)-5-hydroxy-2,9,12-trioxo-7-(4-pyridin-2-ylbenzyl)-13-oxa-3,7,8,11-tétraazatétradéc-1-yl]carbamate de méthyle sulfate (salt); Methyl {(5S,10S,11S,14S)-11-benzyl-10-hydroxy-15,15-dimethyl-5-(2-methyl-2-propanyl)-3,6,13-trioxo-8-[4-(2-pyridinyl)benzyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl}cbamate; ((5S,6S)-5-hydroxy-1,8-dioxo-6-(phenyl methyl)-3-[[4-(2- pyridinyl)phenyl]methyl] -2,3,7 triaza octane dioic acid tertiy butyl ester); Atazanavir Sulfate; ATAZANAVIR SULPHATE [DRUG SUBSTANCE (NON-STERILE)]; Aids-060276; Atazanavir (sulfate); ATAZANAVIR SULFATE (BMS-232632 SULFATE); BMS 232632 SULFATE;BMS-232632 SULFATE;BMS232632 SULFATE; Azanavir sulfate; BMS232632 sulfate; Methyl N-[(1S)-1-{[(2S,3S)-3-hydroxy-4-[(2S)-2-[(Methoxycbonyl)amino]-3,3-diMethyl-N'-{[4-(pyridin-2-yl)phenyl]Methyl}butanehydrazido]-1-phenylbutan-2-yl]cbaMoyl}-2,2-diMethylpropyl]cbaMate; 2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester, (3S,8S,9S,12S)-, sulfate (1:1) (salt); Atazanavir sulfate //BP; BMS-232632-05; Cgp; Aids060276; Atazanavir sulfate, 10 mM in DMSO; (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioic acid 1,14-dimethyl ester, sulfate (1:1); Methyl N-[(2S)-1-[[(2S,3S)-3-hydroxy-4-[[[(2S)-2-(methoxycbonylamino)-3,3-dimethylbutanoyl]amino]-[(4-pyridin-2-ylphenyl)methyl]amino]-1-phenylbutan-2-yl]amino]-3,3-dimethyl-1-oxobutan-2-yl]cbamate sulfate; Reyataz {Sulfate}; methyl((5S,10S,11S,14S)-11-benzyl-5-(tert-butyl)-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-(4-(pyridin-2-yl)benzyl)-2-oxa-4,7,8,12-tetraazahexadecan-14-yl)cbamatesulfate; BMS-232632 sulfate; butanoic acid, 2-[(methoxycarbonyl)amino]-3,3-dimethyl-, 2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethyl-1-oxobutyl]amino]-4-phenylbutyl]-2-[[4-(2-pyridinyl)phenyl]methyl]hydrazi; de, (2S)-, sulfate (1:1) (salt); 1-(4-Biphenylyl)-4(S)-hydroxy-5(S)-2,5-bis{[N-(methoxycbonyl-)-L-tert-leucinyl]amino}-6-phenyl-2-azahexane; Atazanavir sulfate RS; Atazanavir sulfate CRS; Methyl-[(1S,4S,5S,10S)-4-benzyl-1,10-di-tert-butyl-5-hydroxy-2,9,12-trioxo-7-(4-pyridin-2-ylbenzyl)-13-oxa-3,7,8,11-tetraazatetradec-1-yl]carbamatsulfat(salt); Atazanavir Sulphate

物化性质

• 密度: 1.164g/cm3
• 沸点: 995.5ºC at 760 mmHg
• 熔点: 195.0°, or acetone; mp 198-199° (dec)
• 分子式: C₃₈H₅₄N₆O₁₁S
• 分子量: 802.934
• 闪点: 555.8ºC
• 精确质量: 802.357117
• PSA: 254.20000
• LogP: 6.20320
• 外观性状: 固体;White to Almost white powder to crystal
• 蒸汽压: 0mmHg at 25°C
• 储存条件: <0°C;存放于惰性气体之中;避免空气,加热

生物活性

• 描述: Atazanavir硫酸盐是HIV-1蛋白酶高活性抑制剂。
• 相关类别:
  信号通路 >> 代谢酶/蛋白酶 >> HIV蛋白酶
  信号通路 >> 抗感染 >> HIV
  研究领域 >> 感染
• 参考文献:

  [1]. Piliero PJ. Atazanavir: A novel once-daily protease inhibitor. Drugs Today (Barc). 2004 Nov;40(11):901-12.

  [2]. Fukushima K, et al. Effect of serum lipids on the pharmacokinetics of atazanavir in hyperlipidemic rats. Biomed Pharmacother. 2009 Nov;63(9):635-42.

安全

• 符号: GHS05, GHS08
• 信号词: Danger
• 危害声明: H318-H372
• 警示性声明: P260-P280-P305 + P351 + P338 + P310
• 靶器官: Heart, Liver
• 危害码 (欧洲): Xi
• 安全声明 (欧洲): 24/25
• 危险品运输编码: NONH for all modes of transport